. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: Cancer. 2017 Jun 16;123(17):3229–3240. doi: 10.1002/cncr.30826

Table 1. Summary of M-HLH clinical outcomes across different institutions.

Study	Number of patients	Most frequent associated malignancy	6-month survival rate	Median survival (months)
Tamamyam et al.³³ (2016)	35	AML/MDS (n=13), T-lymphoma (n=10), DLBCL (n=6), HL (n=6), CLL (n=4), CML (n=2), Follicular lymphoma (n=2)	30%	2.0
Parikh et al.²³ (2014)	32	T-lymphoma (n=19), DLBCL (n=6), EBV-associated PTLD (n=3), HL (n=1), CMML (n=1), hemangioendothelioma (n=1), systemic histiocytosis (n=1)	Not reported	1.4
Otrock et al.³² (2015)	21	B-neoplasms (n=10), T-neoplasms (n=6), HL (n=3), AML (n=1), MDS (n=1)	20%	1.1
Lehmberg et al.²⁵ (2015)	21	T-neoplasms (n=12), B-neoplasms (n=7)	67%	1.2
Machaczka et al.¹⁰ (2011)	8	HL (n=2), MM (n=2), 1 each of B-CLL, PTCL, AILD, WM, ATL	38%	2.4
Shabbir et al.²⁴ (2011)	6	AML (n=2), T-cell lymphoma (n=2), post auto-SCT for MM (n=2)	Not reported	1.2 (entire adult HLH cohort, n=18)

AML, acute myeloid leukemia, MDS, myelodysplastic syndrome, DLBCL, diffuse large B-cell lymphoma, CLL, chronic lymphocytic leukemia, CML, chronic myeloid leukemia, HL, hodgkins lymphoma, MM, multiple myeloma, PTCL, peripheral T-cell lymphoma, AILD, angioimmunoblastic lymphadenopathy, WM, Waldenstorms macroglobulinemia, ATL, adult T-cell leukemia, SCT, stem cell transplant, PTLD, post-transplant lymphoproliferative disorder, CMML, chronic myelomonocytic leukemia.